Amgen Inc. AMGN | NASDAQ
After Hours
Next Earnings: Aug 04, 2025
Company Overview:
10 Year AMGN Performance Metrics:
AMGN Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
AMGN Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
AMGN Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
AMGN Dividends Info:
AMGN Dividend History: Dates, Payments & Yield list
Below is a schedule of all AMGN dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 05/16/2025 | 06/06/2025 | $2.380 | 3.4% | 3.28% | $290.33 |
| 02/14/2025 | 03/07/2025 | $2.380 | 3.14% | 2.93% | $324.86 |
| 11/18/2024 | 12/09/2024 | $2.250 | 3.23% | 3.24% | $277.63 |
| 08/16/2024 | 09/06/2024 | $2.250 | 2.76% | 2.81% | $320.56 |
| 05/17/2024 | 06/07/2024 | $2.250 | 0% | 2.95% | $305.02 |
| 05/16/2024 | 06/07/2024 | $2.250 | 2.78% | 2.95% | $305.02 |
| 02/15/2024 | 03/07/2024 | $2.250 | 2.99% | 3.3% | $272.86 |
| 11/16/2023 | 12/08/2023 | $2.130 | 3.17% | 3.17% | $269.12 |
| 08/17/2023 | 09/08/2023 | $2.130 | 3.16% | 3.28% | $259.43 |
| 05/17/2023 | 06/08/2023 | $2.130 | 3.62% | 3.86% | $220.76 |
| 02/14/2023 | 03/08/2023 | $2.130 | 3.3% | 3.73% | $228.43 |
| 11/16/2022 | 12/08/2022 | $1.940 | 2.73% | 2.72% | $285.57 |
| 08/17/2022 | 09/08/2022 | $1.940 | 3.03% | 3.16% | $245.45 |
| 05/16/2022 | 06/08/2022 | $1.940 | 3.03% | 3.16% | $245.48 |
| 02/14/2022 | 03/08/2022 | $1.940 | 3.22% | 3.36% | $231.10 |
| 11/15/2021 | 12/08/2021 | $1.760 | 3.39% | 3.3% | $213.53 |
| 08/16/2021 | 09/08/2021 | $1.760 | 2.98% | 3.19% | $220.87 |
| 05/14/2021 | 06/08/2021 | $1.760 | 2.67% | 2.97% | $236.82 |
| 02/11/2021 | 03/08/2021 | $1.760 | 2.79% | 3.09% | $227.81 |
| 11/13/2020 | 12/08/2020 | $1.600 | 2.7% | 2.8% | $228.94 |
| 08/14/2020 | 09/08/2020 | $1.600 | 2.61% | 2.65% | $241.18 |
| 05/15/2020 | 06/08/2020 | $1.600 | 2.54% | 2.83% | $225.75 |
| 02/13/2020 | 03/06/2020 | $1.600 | 2.67% | 3.04% | $210.65 |
| 11/14/2019 | 12/06/2019 | $1.450 | 2.65% | 2.48% | $233.77 |
| 08/14/2019 | 09/06/2019 | $1.450 | 2.85% | 2.79% | $207.73 |
| 05/16/2019 | 06/07/2019 | $1.450 | 3.26% | 3.3% | $175.51 |
| 02/14/2019 | 03/08/2019 | $1.450 | 2.9% | 3.21% | $180.87 |
| 11/15/2018 | 12/07/2018 | $1.320 | 2.74% | 2.76% | $191.44 |
| 08/16/2018 | 09/07/2018 | $1.320 | 2.6% | 2.69% | $196.30 |
| 05/16/2018 | 06/08/2018 | $1.320 | 2.84% | 2.86% | $184.30 |
| 02/14/2018 | 03/08/2018 | $1.320 | 2.66% | 2.82% | $187.16 |
| 11/16/2017 | 12/08/2017 | $1.150 | 2.69% | 2.62% | $175.41 |
| 08/15/2017 | 09/08/2017 | $1.150 | 2.62% | 2.55% | $180.64 |
| 05/15/2017 | 06/08/2017 | $1.150 | 2.69% | 2.83% | $162.65 |
| 02/13/2017 | 03/08/2017 | $1.150 | 2.48% | 2.59% | $177.78 |
| 11/14/2016 | 12/08/2016 | $1.000 | 2.73% | 2.85% | $140.59 |
| 08/15/2016 | 09/08/2016 | $1.000 | 2.17% | 2.34% | $170.97 |
| 05/13/2016 | 06/08/2016 | $1.000 | 2.35% | 2.53% | $158.00 |
| 02/11/2016 | 03/08/2016 | $1.000 | 2.38% | 2.77% | $144.63 |
| 11/12/2015 | 12/07/2015 | $0.790 | 2.09% | 2% | $158.30 |
| 08/13/2015 | 09/08/2015 | $0.790 | 1.77% | 2.04% | $154.56 |
| 05/12/2015 | 06/05/2015 | $0.790 | 1.77% | 2.01% | $157.25 |
| 02/10/2015 | 03/06/2015 | $0.790 | 1.72% | 2.04% | $154.88 |
| 11/10/2014 | 12/05/2014 | $0.610 | 1.5% | 1.44% | $169.24 |
| 08/12/2014 | 09/05/2014 | $0.610 | 1.82% | 1.77% | $137.88 |
| 05/13/2014 | 06/06/2014 | $0.610 | 1.95% | 2.07% | $117.82 |
| 02/11/2014 | 03/07/2014 | $0.610 | 1.67% | 2% | $122.26 |
| 11/12/2013 | 12/06/2013 | $0.470 | 1.67% | 1.65% | $114.12 |
| 08/14/2013 | 09/06/2013 | $0.470 | 1.66% | 1.69% | $111.01 |
| 05/14/2013 | 06/07/2013 | $0.470 | 1.54% | 1.9% | $98.81 |
| 02/11/2013 | 03/07/2013 | $0.470 | 1.83% | 2.02% | $92.95 |
| 11/13/2012 | 12/07/2012 | $0.360 | 1.68% | 1.63% | $88.32 |
| 08/14/2012 | 09/07/2012 | $0.360 | 1.63% | 1.72% | $83.96 |
| 05/14/2012 | 06/07/2012 | $0.360 | 1.82% | 2.08% | $69.10 |
| 02/13/2012 | 03/07/2012 | $0.360 | 1.35% | 2.15% | $66.95 |
| 11/15/2011 | 12/08/2011 | $0.280 | 0.99% | 1.92% | $58.40 |
| 08/16/2011 | 09/08/2011 | $0.280 | 0.55% | 2.02% | $55.31 |
Projected Future Returns & Dividends for AMGN
Based on past 10-year performance, here are AMGN growth metrics:
Share price CAGR of +6.16%
Dividend CAGR of +11.66%
Using AMGN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| AMGN (DRIP) | AMGN - No DRIP | |
|---|---|---|
| Current Price | $279.21 | $279.21 |
| Start Shares | 35.82 | 35.82 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 55.06 | 35.82 |
| Dividends Payment | $7.17 | $7.17 |
| Annual Dividends | $1,579 | $1,027 |
| Yield on cost | 15.79% | 10.27% |
| Share Price | $478.32 | $478.32 |
| Total Dividends | $7,464 | $5,886 |
| Final Value | $26,336 | $23,017 |
NOTE: Above numbers are our estimate based on AMGN's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Amgen Inc. (AMGN) had its IPO on 1983-06-17, and is trader on NASDAQ stock exchange.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN website: https://www.amgen.com
